Q-omics provides the consensus-scored PTCHD3P3 profile across patient tissues and cancer cell-line models. PTCHD3P3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PTCHD3P3 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, PTCHD3P3 RNA expression shows 11,570 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, and LSCC as cancer lineages where PTCHD3P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTCHD3P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTCHD3P3 survival associations across molecular data types. PTCHD3P3 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTCHD3P3 RNA expression–survival associations across cancer types. High PTCHD3P3 expression shows unfavorable associations in HNSC, UVM, LAML, BLCA, SKCM and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PTCHD3P3 RNA expression.
This table summarizes PTCHD3P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PTCHD3P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTCHD3P3 shows lower tumor expression in KICH and KIRP and higher tumor expression in HNSC, LUSC, COAD and STAD. The HNSC box plot shows higher PTCHD3P3 RNA expression in tumor versus normal tissue (log2 FC = +0.164, t-test p < 0.001).
This table shows molecular features associated with PTCHD3P3 in patient tissues and cancer cell lines. In patient samples, PTCHD3P3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
